Article
Clinical Neurology
Sepehr Mamoei, Henrik Boye Jensen, Andreas Kristian Pedersen, Mikkel Karl Emil Nygaard, Simon Fristed Eskildsen, Ulrik Dalgas, Egon Stenager
Summary: In a 1-year longitudinal study, responders and non-responders to Fampridine treatment among persons with multiple sclerosis were compared in terms of disability measures, physical and cognitive performance tests, neurophysiology, and MRI outcomes. Non-responders were found to have prolonged peripheral motor conduction times compared to responders. The study also showed associations between certain tests and measurements, such as the six spot step test with central motor conduction times and the symbol digit modalities test with T2-weighted lesion characteristics.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Gabriel Pardo, Samantha Coates, Darin T. Okuda
Summary: Various instruments have been developed to assess disease stability or progression in individuals with multiple sclerosis, providing clinicians with valuable tools to optimize therapy. Technological advancements, such as wearable sensors, offer new opportunities to better understand changes in MS-related symptoms and impairment. Continued research and development have significantly improved the management and evaluation of MS in recent decades.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Seyed H. Mousavi, Paxton Gehling, Kim J. Buchiel
Summary: Radiofrequency lesioning (RFL) is an effective treatment for trigeminal neuralgia secondary to multiple sclerosis, providing long-term pain relief and the possibility of repeat procedures.
Article
Clinical Neurology
Cecilie Dollerup Skov, Christina Borgen Sorensen, Maria Thorning, Kate Lykke Lambertsen, Lars Henrik Frich, Henrik Boye Jensen, Anders Holsgaard-Larsen, Helle H. Nielsen
Summary: The purpose of this study was to evaluate changes in functional hand and walking measurements in multiple sclerosis patients with walking disability after fampridine treatment. The combination of self-reported walking capacity and walking endurance was found to be the most effective measurement for detecting clinically meaningful improvement after fampridine treatment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Ali Amini Harandi, Hossein Pakdaman, Faezeh Karamiani, Faezeh Mohammadi, Siavash Shirzadeh Barough, Fatemeh Siavoshi, Saba Ilkhani, Mohammadali Sahraian
Summary: Using fampridine plus IVMP in the acute phase of transverse myelitis in MS patients improved the disease's symptoms and increased the daily activity ability of patients.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Maria A. Rocca, Paola Valsasina, Bruno Colombo, Vittorio Martinelli, Massimo Filippi
Summary: Fatigue in multiple sclerosis patients improved regardless of treatment. Changes in resting state functional connectivity were located in sensorimotor, inferior frontal, and subcortical regions for fampridine- and amantadine-treated patients, while in associative sensory cortices for placebo-treated patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Clinical Neurology
Sahar Ghorbanpour, Sarvenaz Rahimibarghani, Setareh Rohani, Mohsen Rastkar, Mahsa Ghajarzadeh
Summary: This systematic review and meta-analysis found that fampridine improves gait imbalance in patients with multiple sclerosis (MS).
NEUROLOGICAL SCIENCES
(2023)
Article
Engineering, Biomedical
Maria Thorning, Helle Hvilsted Nielsen, Lars Henrik Frich, Henrik Boye Jensen, Kate Lykke Lambertsen, Anders Holsgaard-Larsen
Summary: The study aimed to investigate the effects of Fampridine treatment on gait quality and function in patients with multiple sclerosis. The findings showed that while Fampridine treatment improved gait function, there was no change in the overall kinematic quality of gait.
CLINICAL BIOMECHANICS
(2022)
Article
Clinical Neurology
Olivier Rascol, Valerie Cochen de Cock, Anne Pavy-Le Traon, Alexandra Foubert-Samier, Claire Thalamas, Agnes Sommet, Vanessa Rousseau, Santiago Perez-Lloret, Margherita Fabbri, Jean Philippe Azulay, Jean-Christophe Corvol, Philippe Couratier, Philippe Damier, Luc Defebvre, Franck Durif, Christian Geny, Jean-Luc Houeto, Philippe Remy, Christine Tranchant, Marc Verin, Francois Tison, Wassilios G. Meissner
Summary: The study aimed to evaluate the efficacy and safety of fluoxetine in the symptomatic treatment of multiple system atrophy (MSA). Results showed greater improvement in UMSARS Part II and MSA-QoL emotional/social dimension in the fluoxetine group, but no significant difference in the total UMSARS score compared to placebo. Further investigation is needed to understand the trends in motor and emotional secondary/exploratory outcomes.
MOVEMENT DISORDERS
(2021)
Article
Clinical Neurology
Isabel Lutfullin, Maria Eveslage, Stefan Bittner, Gisela Antony, Martina Flaskamp, Felix Luessi, Anke Salmen, Barbara Gisevius, Luisa Klotz, Catharina Korsukewitz, Achim Berthele, Sergiu Groppa, Florian Then Bergh, Brigitte Wildemann, Antonios Bayas, Hayrettin Tumani, Sven G. Meuth, Corinna Trebst, Uwe K. Zettl, Friedemann Paul, Christoph Heesen, Tania Kuempfel, Ralf Gold, Bernhard Hemmer, Frauke Zipp, Heinz Wiendl, Jan D. Luenemann
Summary: Obesity is associated with higher disease severity and poorer outcome in newly diagnosed patients with multiple sclerosis. The presence of obesity at disease onset is linked to higher disability at baseline and at follow-up periods of 2, 4, and 6 years. Obesity management could potentially improve the clinical outcome of multiple sclerosis.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Mona Klara Ros Mueller, Monika Christ, Markus Naumann, Antonios Bayas
Summary: This article reports a case of spinal myoclonus in a patient with multiple sclerosis after cervical myelitis, which significantly improved after treatment with prolonged-release fampridine.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2022)
Article
Medicine, Research & Experimental
Peter Kosa, Ruturaj Masvekar, Mika Komori, Jonathan Phillips, Vighnesh Ramesh, Mihael Varosanec, Mary Sandford, Bibiana Bielekova
Summary: This study aimed to enhance the clinical value of serum neurofilament light chain (sNFL) through mathematical adjustment. The results showed that adjustment including age, blood urea nitrogen, alkaline phosphatase, creatinine, and weight significantly improved the correlations between sNFL and cerebrospinal fluid NFL (cNFL), as well as the correlations with the number of lesions in multiple sclerosis patients. In addition, there was a weak but significant correlation between sNFL and cross-sectional severity outcomes in multiple sclerosis.
Article
Gastroenterology & Hepatology
David M. de Jong, Yoklan L. Mulder, J. L. van Dam, Bas Groot Koerkamp, Marco J. Bruno, Pieter Jan F. de Jonge
Summary: This study retrospectively investigated the success and adverse event rates of endoscopic therapy for symptomatic HJAS after PD. The results showed a moderate technical success rate and a high recurrence rate. Future studies should optimize treatment protocols and compare different treatment methods.
Review
Cell Biology
Viktoria Gudi, Pawel Grieb, Ralf A. Linker, Thomas Skripuletz
Summary: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, resulting in demyelination and functional disability. CDP-choline, a compound with regenerative properties, has been shown to improve myelin regeneration in animal models of multiple sclerosis. However, its effects in human patients have not been studied yet.
NEURAL REGENERATION RESEARCH
(2023)
Article
Clinical Neurology
Katie L. J. Cederberg, Brenda Jeng, Jeffer E. Sasaki, E. Morghen Sikes, Stephanie L. Silveira, Gary Cutter, Robert W. Motl
Summary: This study found that anxiety, fatigue, depression, and unemployment were associated with worse sleep quality in adults with multiple sclerosis. Specific subgroups within the MS population were identified as experiencing more sleep problems and in greatest need for interventions targeting sleep impairment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Philipp Karschnia, Jacob S. Young, Antonio Dono, Levin Haeni, Tommaso Sciortino, Francesco Bruno, Stephanie T. Juenger, Nico Teske, Ramin A. Morshed, Alexander F. Haddad, Yalan Zhang, Sophia Stoecklein, Michael Weller, Michael A. Vogelbaum, Juergen Beck, Nitin Tandon, Shawn Hervey-Jumper, Annette M. Molinaro, Roberta Ruda, Lorenzo Bello, Oliver Schnell, Yoshua Esquenazi, Maximilian Ruge, Stefan J. Grau, Mitchel S. Berger, Susan M. Chang, Martin van den Bent, Joerg-Christian Tonn
Summary: This study investigated the prognostic value of the extent of resection in glioblastoma, finding that smaller volumes of residual contrast-enhancing tumor were associated with better outcomes. Additionally, removing non-contrast-enhancing tumor beyond the tumor borders resulted in improved survival. These findings have significant implications for stratification in clinical trials.
Article
Oncology
Marcel Buehler, Xiao Yi, Weigang Ge, Peter Blattmann, Elisabeth Rushing, Guido Reifenberger, Joerg Felsberg, Charles Yeh, Jacob E. Corn, Luca Regli, Junyi Zhang, Ann Cloos, Vidhya M. Ravi, Benedikt Wiestler, Dieter Henrik Heiland, Ruedi Aebersold, Michael Weller, Tiannan Guo, Tobias Weiss
Summary: In this study, the evolution of the proteomic landscape in glioblastoma from initial diagnosis to post-treatment recurrence was investigated. The authors identified BCAS1, INF2, and FBXO2 as consistently upregulated proteins at recurrence, and demonstrated that knockout of the FBXO2 gene conferred a survival benefit and reduced invasive growth. These findings suggest a potential role of FBXO2 in promoting tumor growth through glioma-microenvironment interactions.
Article
Oncology
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.
Article
Oncology
Philipp Vollmuth, Martha Foltyn, Raymond Y. Huang, Norbert Galldiks, Jens Petersen, Fabian Isensee, Martin J. van den Bent, Frederik Barkhof, Ji Eun Park, Yae Won Park, Sung Soo Ahn, Gianluca Brugnara, Hagen Meredig, Rajan Jain, Marion Smits, Whitney B. Pope, Klaus Maier-Hein, Michael Weller, Patrick Y. Wen, Wolfgang Wick, Martin Bendszus
Summary: This study aimed to assess the reproducibility and standardization of treatment response assessment using artificial intelligence (AI) decision support in MRI. The results showed that AI decision support can provide better evaluation of treatment response in patients with lower-grade gliomas compared to manual measurements.
Article
Oncology
Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurel Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Froehlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Gruener, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K. H. van Landeghem, Torsten Pietsch, Jorg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Bruestle, Matthias Simon, Martin Glas, Bjoern Scheffler
Summary: This study aimed to identify and target tumor cells that can survive, adapt, and expand under primary therapy in glioblastoma. The researchers found that ALDH1A1+/pAKT+ subclones accumulate and acquire drug resistance in response to temozolomide treatment. They propose a combination therapy of temozolomide and AKT inhibitors as a potential treatment strategy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. Mellinghoff, L. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen
Summary: This article discusses the diagnosis and management of IDH-mutant gliomas, as well as new treatment methods and future research directions.
Article
Clinical Neurology
Romina Willi, Mario Widmer, Nora Merz, Caroline H. G. Bastiaenen, Bjoern Zoerner, Marc Bolliger
Summary: The aim of this study was to assess the construct validity and test-retest reliability of the 2mWT in individuals with SCI. The results showed that the 2mWT had a strong correlation with the 6mWT and 10MWT, and a moderate correlation with the WISCI II. Walking performance slightly affected the sensitivity to change. Therefore, the 2mWT is a valid and reliable alternative to measure walking function in individuals with SCI.
Article
Clinical Neurology
Katharina Seystahl, Juliane Schweizer, Mira Katan, Sung Ju Weber, Alessia Hug, Miriam Wanner, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
Summary: Cancer is not a risk factor for stroke-associated infections in stroke patients. The incidence, characteristics, and treatment of infections did not differ significantly between stroke patients with and without cancer. However, both cancer and stroke-associated infections were associated with in-hospital mortality.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio
Summary: The conditions that promote immunotherapy responses in primary or secondary brain malignancies were discussed during the V Siena Immuno-Oncology (IO) Think Tank meeting in 2021. Important publications in 2021 and 2022 have reinforced the core elements of these discussions. While current immunotherapies have failed to benefit patients with primary brain tumors like glioblastoma, they have shown positive responses in brain metastases. The differences between these conditions seem to be influenced by intrinsic and extrinsic factors, such as driver mutations, the blood-brain barrier, and the immune suppressive microenvironment. Future therapeutic interventions may focus on rebalancing the immune cell population to enable better responses to current and future immunotherapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Corinna Seliger, Felix Boakye Oppong, Florence Lefranc, Olivier Chinot, Roger Stupp, Burt Nabors, Thierry Gorlia, Michael Weller, EORTC Brain Tumor Group
Summary: Depressive symptoms are common in glioblastoma patients, but they are often not treated with antidepressants. Limited evidence suggests that the use of antidepressants is not significantly associated with progression-free or overall survival in glioblastoma patients. However, using antidepressants at the start of maintenance cycle 4 is significantly associated with worse overall survival. Antidepressant use is not significantly associated with seizures, cognitive changes, or fatigue, except for an increase in fatigue during maintenance treatment. Confirmation and further study are needed to assess the impact of antidepressant use on the survival of glioblastoma patients. Prospective trials should evaluate the efficacy, side effects, and outcomes of antidepressant treatment in glioblastoma.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Chemistry, Analytical
Anne Schwarz, Adib Al-Haj Husain, Lorenzo Einaudi, Eva Thurlimann, Julia Laderach, Chris Awai Easthope, Jeremia P. O. Held, Andreas R. Luft
Summary: The study aims to investigate the reliability and validity of a sensor-based gait analysis system in stroke survivors. The results show that the system has good test-retest reliability and correlates with clinical assessment tools, indicating its applicability in gait rehabilitation for stroke patients.
Article
Oncology
Evelina Blomberg, Manuela Silginer, Patrick Roth, Michael Weller
Summary: Despite various treatment approaches, the survival rate for glioblastoma patients remains low. This study implicates that constitutive type I interferon signaling in gliomas may promote tumor growth, but only in a microenvironment with a proficient type I interferon signaling in the host.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Katharina Seystahl, Dorothee Gramatzki, Miriam Wanner, Sung Ju Weber, Alessia Hug, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
Summary: The occurrence of cancer in stroke patients can be associated with elevated levels of white blood cells, platelets, and d-dimers. Additionally, the presence of ischemic lesions in multiple vascular territories is also linked to cancer diagnosis within one year after stroke.
SCIENTIFIC REPORTS
(2023)